Vider Etty, Sapir Ravit, Mosseri Eli, Gavioli Elizabeth
Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Brooklyn, NY.
J Cardiovasc Pharmacol. 2022 Mar 1;79(3):247-253. doi: 10.1097/FJC.0000000000001176.
Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) are a relatively new class of drugs approved for the treatment of type 2 diabetes. In 2021, the American College of Cardiology recommended the use of SGLT-2 inhibitors in patients with heart failure (HF), with or without type 2 diabetes, because of their morbidity and mortality benefits. The review provides an overview of the efficacy and safety of SGLT-2 inhibitors in HF and chronic kidney disease (CKD). We review the existing literature for SGLT-2 inhibitors by searching PubMed.gov using the keywords SGLT-2 inhibitors, HF, and CKD. A clinical treatment pathway is provided to help guide clinicians in choosing an SGLT-2 inhibitor for their patients with chronic HF and CKD.
钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2抑制剂）是一类相对较新的获批用于治疗2型糖尿病的药物。2021年，美国心脏病学会建议，无论是否患有2型糖尿病，心力衰竭（HF）患者均可使用SGLT-2抑制剂，因为其具有降低发病率和死亡率的益处。本综述概述了SGLT-2抑制剂在心力衰竭和慢性肾脏病（CKD）中的疗效和安全性。我们通过在PubMed.gov上搜索关键词“SGLT-2抑制剂”“心力衰竭”和“慢性肾脏病”来回顾SGLT-2抑制剂的现有文献。本文提供了一条临床治疗路径，以帮助指导临床医生为慢性心力衰竭和慢性肾脏病患者选择SGLT-2抑制剂。
